Literature DB >> 19120278

Risk conferred by HLA-DR and DQ for type 1 diabetes in 0-35-year age group in Sweden.

Carani B Sanjeevi1, Saikiran K Sedimbi, Mona Landin-Olsson, Ingrid Kockum, Ake Lernmark.   

Abstract

UNLABELLED: HLA DR4-DQ8 and DR3-DQ2 haplotypes account for 89% of newly diagnosed cases of type 1 diabetes (T1D) in Sweden. The presence of a single copy of DQ6 confers protection. The aim of the present study is to evaluate whether the risk conferred by high risk HLA DR and DQ to T1D is similar in all regions of Sweden and see whether there are any significant regional differences. The subjects comprised 799 consecutively diagnosed T1D patients and 585 age-, sex-, and geography-matched healthy controls in the age group 0-35 years. HLA typing for high-risk haplotypes was previously performed using PCR-SSOP and RFLP. The results showed that HLA DR3-DR4 gave an odds ratio of 8.14 for the whole of Sweden. However, when the study group was divided into six geographical regions, subjects from Stockholm had the highest OR, followed by those from Lund, Linköping, Gothenburg, Umeå, and Uppsala. Absolute protection was conferred by the presence of DQ6 in subjects from the Linköping region, but varied in the other regions. The frequency of DR3 and DQ2, DR4 and DQ8, DR15, and DQ6 in patients showed high linkage for each region, but were different between regions. IN
CONCLUSION: The risk conferred by high-risk HLA varies in different regions for a homogenous population in Sweden. The results highlight the important role played by the various environmental factors in the precipitation of T1D.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19120278     DOI: 10.1196/annals.1447.061

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  Celiac sprue: a unique autoimmune disorder.

Authors:  Shadi Rashtak; Eric V Marietta; Joseph A Murray
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

Review 2.  Type 1 diabetes and polyglandular autoimmune syndrome: A review.

Authors:  Martin P Hansen; Nina Matheis; George J Kahaly
Journal:  World J Diabetes       Date:  2015-02-15

3.  Species neutral correlates of immunogenicity for vaccines and protein therapeutics: fact or science fiction.

Authors:  Anne S De Groot; Matthew Baker; Tobias Cohen
Journal:  Hum Vaccin       Date:  2010-05

4.  Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.

Authors:  Hillary A Keenan; Jennifer K Sun; Jared Levine; Alessandro Doria; Lloyd P Aiello; George Eisenbarth; Susan Bonner-Weir; George L King
Journal:  Diabetes       Date:  2010-08-10       Impact factor: 9.461

5.  A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM).

Authors:  Tobias Cohen; Leonard Moise; Matthew Ardito; William Martin; Anne S De Groot
Journal:  J Biomed Biotechnol       Date:  2010-07-18

6.  Low risk HLA-DQ and increased body mass index in newly diagnosed type 1 diabetes children in the Better Diabetes Diagnosis study in Sweden.

Authors:  A Carlsson; I Kockum; B Lindblad; L Engleson; A Nilsson; G Forsander; A-K Karlsson; A Kernell; J Ludvigsson; C Marcus; I Zachrisson; S-A Ivarsson; A Lernmark
Journal:  Int J Obes (Lond)       Date:  2011-06-28       Impact factor: 5.095

7.  Size for gestational age affects the risk for type 1 diabetes in children and adolescents: a Swedish national case-control study.

Authors:  Nina Lindell; Marie Bladh; Annelie Carlsson; Ann Josefsson; Karin Aakesson; Ulf Samuelsson
Journal:  Diabetologia       Date:  2021-02-05       Impact factor: 10.122

Review 8.  Animal models to study gluten sensitivity.

Authors:  Eric V Marietta; Joseph A Murray
Journal:  Semin Immunopathol       Date:  2012-05-11       Impact factor: 11.759

9.  Prevalence of obesity was related to HLA-DQ in 2-4-year-old children at genetic risk for type 1 diabetes.

Authors:  J Yang; Å Lernmark; U M Uusitalo; K F Lynch; R Veijola; C Winkler; H E Larsson; M Rewers; J-X She; A G Ziegler; O G Simell; W A Hagopian; B Akolkar; J P Krischer; K Vehik
Journal:  Int J Obes (Lond)       Date:  2014-04-03       Impact factor: 5.551

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.